# M Ventures

> M Ventures is a VC fund in Amsterdam backing Biotechnology and Health Care. See 175 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Amsterdam, The Netherlands
- Total investments: 175
- Last investment: Jul 2026
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/merck-ventures/
- X (Twitter): https://twitter.com/merckventures
- Website: https://www.m-ventures.com/
- Facebook: https://www.facebook.com/M-Ventures-1599894756968485/

M Ventures is a VC fund in Amsterdam focused on Biotechnology and Health Care. Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

## Contacts

5 contacts available for M Ventures. Shizune tracks 23 team members at M Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/merckventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.4M–$24M |
| Series A | $5.6M–$50M |
| Series B | $15M–$100M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 62 | 35% |
| Health Care | 38 | 22% |
| Therapeutics | 30 | 17% |
| Medical | 20 | 11% |
| Pharmaceutical | 15 | 9% |

81 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 59 | 34% |
| Series B | 33 | 19% |
| Seed | 28 | 16% |
| Series C | 14 | 8% |
| Funding Round | 7 | 4% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 46 | 26% |
| United Kingdom | 14 | 8% |
| Switzerland | 11 | 6% |
| Germany | 9 | 5% |
| France | 6 | 3% |

13 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Christian Patze | Associate, Performance Materials | 1 | https://shizune.co/investors/profile/christian-patze |
| Noga Yerushalmi | Head of Israel Bio-incubator | 2 | https://shizune.co/investors/profile/noga-yerushalmi |
| Sarah Luppino | Associate | 1 | https://shizune.co/investors/profile/sarah-luppino |
| Alexander Hoffmann | Principal | 8 | https://shizune.co/investors/profile/alexander-hoffmann |
| Alicia Iruzun Lafitte | Principal | 4 | https://shizune.co/investors/profile/alicia-iruzun-lafitte |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cyllene Therapeutics | EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy. | $37.7M | Series C | Jul 07, 2026 |  |
| TRIMTECH Therapeutics | TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M | Seed | Jun 23, 2026 |  |
| Future Fertility | Future Fertility is a fertility technology company focused on AI-enabled and non-invasive diagnostic solutions to optimize decision making throughout the IVF journey, maximizing the probability of positive outcomes in IVF workflows. The first product is an egg assessment software, which uniquely provides insights in egg quality and has thepotential to improve success rates of IVF, egg freezing and egg donation cycles. | $4.1M | Series A | Apr 23, 2026 |  |
| Future Fertility | Future Fertility is a fertility technology company focused on AI-enabled and non-invasive diagnostic solutions to optimize decision making throughout the IVF journey, maximizing the probability of positive outcomes in IVF workflows. The first product is an egg assessment software, which uniquely provides insights in egg quality and has thepotential to improve success rates of IVF, egg freezing and egg donation cycles. | $4.1M | Series A | Apr 23, 2026 |  |
| Storm Therapeutics | Targeting pathways that modify RNA to deliver novel cancer therapeutics. | $56M | Series C | Apr 16, 2026 |  |
| Lightcast Discovery | Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.The company's mission is to push the boundaries of complex cell analysis. Using the Lightcast platform, the company is working with major pharmaceutical companies and leading academic institutes to enable them todiscover more. The Lightcast platform allows precise and highly flexible independent control of thousands of droplets. By combining droplets containing different cells, reporters or other reagents we can perform complex workflows without the need to manipulate cells by hand.Lightcast Discovery was founded in 2019 by Cameron Frayling. | $27M | Venture - Series Unknown | Apr 14, 2026 |  |
| ImmuneBridge | ImmuneBridge is developing allogeneic immunotherapies for cancer. ImmuneBridge's key innovation fosters the development of immune stem cells obtained from cord blood and creates a fresh, adaptable, reliable, and plentiful cellular source for immunotherapies. They are currently looking for natural killer cell-based treatments for hematologicalcancers. They will then attack solid tumors using the special benefits of their cellular source. | $7.7M | Seed | Mar 23, 2026 |  |
| Vizgen | Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The highthroughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms. | $48M | Series E | Jan 08, 2026 |  |
| NovoLINC | NovoLINC is a pioneering startup that provides thermal interface solutions. It develops a distinctive system of nanostructured materials and a proprietary manufacturing process with the objective of transforming thermal management. | $10.2M | Seed | Dec 18, 2025 |  |
| FoRx Therapeutics | FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment. FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs. | $50M | Series A | Dec 18, 2025 |  |

10 of 175 investments shown.

## Co-investors
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 14 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 11 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 11 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 10 deals together
- [Koch Disruptive Technologies](https://shizune.co/investors/profile/koch-disruptive-technologies) — VC Fund, 9 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 9 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)
- [Health Care Investors](https://shizune.co/investors/health-care-investors)
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)

## FAQ

### What does M Ventures invest in?

M Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 175 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is M Ventures's check size?

M Ventures typically joins rounds of $2.4M–$24M at Seed, $5.6M–$50M at Series A and $15M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds M Ventures participates in.

### How do I contact M Ventures?

Public channels for M Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at M Ventures?

The team at M Ventures includes Christian Patze (Associate, Performance Materials), Noga Yerushalmi (Head of Israel Bio-incubator) and Sarah Luppino (Associate), among 23 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co